The Asuragen Genetics portfolio employs our proprietary molecular chemistry and informatics capabilities to drive the evolution of precision medicine in inherited disorders.

The AmplideX^® suite of products is designed to solve unmet testing needs in inherited genetic disorders. The technology overcame a 20-year challenge by reliably amplifying the FMR1 gene. This allowed researchers to gain a deeper understanding of fragile X syndrome, the most common known inherited cause of intellectual disability and autism.

Asuragen pioneered innovation in three major areas:

Reduced Complexity
Amplification and analysis of GC-rich and high homology target sequences

Optimized Workflow
Assay and informatics solutions to optimize efficiency, hands-on time and cost

Quality Performance
Accuracy, sensitivity, specificity and reproducibility with FMR1